Increased cysteine metabolism in PINK1 models of Parkinson's disease

Author:

Travaglio Marco12ORCID,Michopoulos Filippos3,Yu Yizhou1ORCID,Popovic Rebeka1ORCID,Foster Edmund4ORCID,Coen Muireann25ORCID,Martins L. Miguel1ORCID

Affiliation:

1. University of Cambridge 1 MRC Toxicology Unit , , Gleeson Building, Tennis Court Road, Cambridge CB2 1QR , UK

2. AstraZeneca 2 Oncology Safety, Clinical Pharmacology & Safety Sciences, R&D , , Cambridge , UK

3. AstraZeneca 3 Oncology R&D, Research & Early Development , , Cambridge , UK

4. AstraZeneca 4 Neuroscience Safety, Clinical Pharmacology & Safety Sciences, R&D , , Cambridge , UK

5. Imperial College 5 Department of Metabolism, Digestion and Reproduction, Faculty of Medicine , , London , UK

Abstract

ABSTRACT Parkinson's disease (PD), an age-dependent neurodegenerative disease, is characterised by the selective loss of dopaminergic neurons in the substantia nigra (SN). Mitochondrial dysfunction is a hallmark of PD, and mutations in PINK1, a gene necessary for mitochondrial fitness, cause PD. Drosophila melanogaster flies with pink1 mutations exhibit mitochondrial defects and dopaminergic cell loss and are used as a PD model. To gain an integrated view of the cellular changes caused by defects in the PINK1 pathway of mitochondrial quality control, we combined metabolomics and transcriptomics analysis in pink1-mutant flies with human induced pluripotent stem cell (iPSC)-derived neural precursor cells (NPCs) with a PINK1 mutation. We observed alterations in cysteine metabolism in both the fly and human PD models. Mitochondrial dysfunction in the NPCs resulted in changes in several metabolites that are linked to cysteine synthesis and increased glutathione levels. We conclude that alterations in cysteine metabolism may compensate for increased oxidative stress in PD, revealing a unifying mechanism of early-stage PD pathology that may be targeted for drug development. This article has an associated First Person interview with the first author of the paper.

Funder

AstraZeneca

Medical Research Council

University of Cambridge

Publisher

The Company of Biologists

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology and Microbiology (miscellaneous),Medicine (miscellaneous),Neuroscience (miscellaneous)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3